SynAct Pharma AB ("SynAct") today announced it will host a conference call on July 7 at 13:00 CEST focused on the positive topline results from the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency.
The call will be hosted by Chairman Dr. Torbjørn Bjerke, CEO Jeppe Øvlesen and CSO Thomas Jonassen. The study’s principal investigator Dr. Mauro Teixeira will also join. The presentation will be in English and is followed by a Q&A session.
The conference call will be broadcast live on the web via the link: https://tv.streamfabriken.com/synact-pharma-2021-07-07
Telephone number for the conference call is:
SE: +46 8 5055 8359
UK: +44 3333 009 267
US: +1 6 467 224 957
The information was submitted, through the agency of the below contact person, for publication on July 2, 2021.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB
Phone: +45 28 44 75 67 Phone: +45 40 15 66 69